GI CANCERS

Oncologist Dr. Milind Javel provides an overview of first- and subsequent-line treatments for patients with cholangiocarcinoma.

Dr Milind Javle discusses challenges that exist in the early identification of cholangiocarcinoma, as well as the benefits of comprehensive molecular profiling.

Expert oncologist Milind Javle, MD, reviews the diagnosis and treatment of intrahepatic cholangiocarcinoma in a 61-year-old who presents with jaundice and changes in stool and urine color.

The FDA has granted orphan drug designation to LYT-200 for the treatment of patients with pancreatic cancer. The drug is currently under investigation in phase 1/2 clinical trial for the treatment of pancreatic cancer and other metastatic solid tumors.

According to Andrew S. Barbas, MD, of Duke Health, the scarcity of testing that can provide accurate results in patients with pancreatic cancer contributes to diagnoses in the advanced stages of the disease and consequently to poor prognoses.

Results from the phase 3 ESCORT-1st trial have demonstrated promise for the combination of camrelizumab and chemotherapy in patients with advanced or metastatic esophageal squamous cell carcinoma.

The novel checkpoint inhibitor, evorpacept induced responses in patients with head and neck squamous cell carcinoma and gastric cancer when used in combination with anticancer therapy and chemotherapy in a phase 1b study.

In an interview with Targeted Oncology, Rachna Shroff, MD, discusses the impact of ivosidenib’s approval on the cholangiocarcinoma space in greater detail.

DF1001 is currently being studied as both a monotherapy and a combination in a phase 1/2 study that is now recruiting across the United States.

Compared with sunitinib, second-line treatment with ripretinib did not improve progression-free survival in patients with gastrointestinal stromal tumor.

The phase 3 COMPOSE trial is the second trial to look at 177Lu-edotreotide in somatostatin receptor-positive disease.

Progression-free survival remained unaffected in patients with advanced biliary tract cancer after clinicians added either ramucirumab or merestinib to first-line chemotherapy.

Efficacy observed with the combination of devimistat and modified FOLFIRINOX in patients with metastatic pancreatic cancer has lead to a negative result in the phase 3 AVENGER 500 clinical trial.

Topline results show that the addition of eryaspase to chemotherapy does not prolong survival in the general advanced pancreatic cancer population, but there may be benefit for those treated with irinotecan.

Significant survival improvement was achieved with durvalumab in combination with chemotherapy as treatment of patients with biliary tract cancer.

Eileen M. O’Reilly, MD, discusses the current treatment landscape for neuroendocrine tumors.

In an interview with Targeted Oncology™, Michael Chuong, MD explained of the validity of the MRI-guided radiation technique for use in patients with pancreatic cancer, how it compares with CT-guided radiation, and how a shift toward MRI-guided radiation may impact patients with pancreatic cancer in the future.

Primary liver cancer death rates vary by region, and much is still to be done in the area of health equity.

NUC-1031, a drug for the first-line treatment of patients with advanced biliary tract cancer, has been granted fast track designation by the FDA.

The FDA has accepted a supplemental biologic application for nivolumab plus ipilimumab and chemotherapy as a potential treatment option for unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.

GenesisCare and Lee Health announce their efforts to transform pancreatic patient survival rates in Florida.

Michael D. Chuong, MD, a radiation oncologist and medical director of Proton Therapy at Miami Cancer Institute, Baptist Health South Florida, discusses the benefits of MRI-guided radiation therapy in pancreatic cancer.

Complete surgical removal of a pancreatic tumor is not possible for most patients. Chemotherapy and radiation therapy are typically recommended to slow tumor growth, but ultimately are not expected to be curative, writes Michael Chuong, MD.

John Marshall, MD, speaks on regorafenib sequencing and relays his thoughts on the future of treatment for metastatic colorectal cancer.

Dr Marshall discusses the impact regorafenib has had in the treatment of metastatic colorectal cancer and describes data from the CORRECT and ReDOS clinical trials.